AbbVie reported a modest Q4 beat (EPS $2.71 vs $2.65; revenue $16.62B vs $16.41B) but shares fell ~3.8% as investors focused on Humira erosion and mixed performance from growth brands. Elevated trading volume and limited new regulatory catalysts leave ABBV exposed to pipeline execution and pricing pressures despite Rinvoq’s prior GCA approval.
